Insights
Rare Disease Funding: A Spotlight on Saudi Arabia
The Gulf Cooperation Council (GCC) region is experiencing significant economic growth including in the healthcare sector, making it a region of interest for pharma and biotech companies. Market leader, Saudi Arabia, has one of the...
Digital Health in the UAE: Trends Post-COVID-19
The UAE's digital health sector is experiencing rapid growth, driven by government support and increased demand post-COVID-19. Revenue is projected to reach $626.20 million by 2024, with further growth to $811.30 million by 2028. Key...
Beyond Borders: French & English HTA Influence in Saudi Arabia
Rising medicine costs and limited healthcare budgets highlight the need to optimize public resource allocation. Many countries conduct healthcare evaluations, led by health technology assessment (HTA) agencies, to decide on reimbursement and access to new...
Medical Devices: Pathways to Market and Future Outlook in the Middle East & Africa
Many governments in the Middle East and Africa are actively working to improve healthcare access and quality. For medical devices specifically, substantial venture capital and government investment as well as greater uptake of private healthcare...
Guide to Successful Distributor and Manufacturer Relationships in the GCC
To enter the GCC market, international pharmaceutical and biotech companies are required to either establish their local presence in the relevant country or work alongside a local distributor registered under the local authorities. In this...
The Evolving Biosimilar Policy Landscape in the Middle East
Biosimilar adoption level can vary depending on factors such as the specific healthcare systems, the regulatory framework, physician and patient acceptance, and the competitor landscape. In the Middle East and Africa, careful consideration of applicable...
HTA Changes in MENA: What Does the Future Hold for New Product Launches in the Region?
There is growing interest in pharmacoeconomic principles across the Middle East and Africa region. The reason for this is in line with global trends, the region is facing a continuous increase in medical costs and...
Commercializing Innovations: Rethinking the Optimal Launch Strategy and Launch Sequencing
From the declining economic growth rate to the increase in inflation at a global level and the spike in interest rates, the Global economy has faced major challenges in the aftermath of the COVID-19 pandemic...
ATMPs: Critical success drivers for the achievement of premium pricing in Saudi Arabia
The Saudi Arabian pharmaceutical market is regarded as one of the fastest growing in the world today, offering opportunities for high-cost innovative therapies, including Advanced Therapy Medicinal Products (ATMPs).
Look Beyond the US and Europe: Discover the untapped potential of the rare disease market in the Middle East
As one of the most attractive and lucrative markets in the Middle East, Saudi Arabia brings a strong opportunity for pharmaceutical and biotech manufacturers to obtain high prices and uptake within the GCC region, where...
